|
|
|
|
||
Re: CombinationsHere is current clinical trials for immune checkpoint inhibitors. BMY https://clinicaltrials.gov/ct2/results?term=nivolumab&pg=1 Merck https://clinicaltrials.gov/ct2/results?term=Pembrolizumab&Search=Search Roche/Genentech https://clinicaltrials.gov/ct2/results?term=Atezolizumab&pg=1 AstraZeneca https://clinicaltrials.gov/ct2/results?term=durvalumab&pg=1 Pfizer/Merck KGaA https://clinicaltrials.gov/ct2/results?term=avelumab&Search=Search Pfizer/Merck KGaA PD-L1 (avelumab) seem to be the one with least number of combination trials. Atlease they seem to be heavily banking on 4-1BB and OX-40 to establish safe and effective dose. If these combinations continue to be disappointed with low ORR like they showed at ASCO 2016, they will be desperate to find suitable combo partner IMO https://clinicaltrials.gov/ct2/show/NCT02554812?term=avelumab&rank=4 |
return to message board, top of board |